CA916798 gene expression is associated with multidrug resistance and predicts progression‑free survival in patients with lung cancer

Duan,Hailing; Yang,Zaixing; Liang,Lan; Zhou,Xiangdong

doi:10.3892/ol.2019.10436

CA916798 gene expression is associated with multidrug resistance and predicts progression‑free survival in patients with lung cancer

Authors:
- Hailing Duan
- Zaixing Yang
- Lan Liang
- Xiangdong Zhou
View Affiliations

Affiliations: Department of Respiratory Disease, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing 400038, P.R. China
Published online on: June 4, 2019 https://doi.org/10.3892/ol.2019.10436
Pages: 1171-1178
Copyright: © Duan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

CA916798 has been identified as a novel multidrug resistance gene in lung cancer cells. However, the expression patterns of CA916798 in tumor tissues prior and subsequent to chemotherapy remain unclear. In the present study, CA916798 expression levels in tumor tissues prior and subsequent to chemotherapy were detected by reverse transcription‑quantitative polymerase chain reaction and immunohistochemistry analysis. The prognostic significance of CA916798 expression in tumor tissues was explored by Kaplan‑Meier survival analysis and Cox proportional hazards regression analysis. The messenger RNA (mRNA) and protein expression levels of CA916798 in tumor tissues were downregulated post‑chemotherapy in chemotherapy‑sensitive patients with lung cancer, but not in chemotherapy‑resistant patients. Downregulation of CA916798 mRNA and protein expression post‑chemotherapy was significantly associated with improved progression‑free survival time. The findings from the present study suggest that platinum‑based chemotherapy may induce the expression of CA916798, and CA916798 may be a promising biomarker to predict chemotherapy resistance and improve therapies for patients with lung cancer.

View Figures

View References

1	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
3	Torre LA, Siegel RL and Jemal A: Lung cancer statistics. Adv Exp Med Biol. 893:1–19. 2016. View Article : Google Scholar : PubMed/NCBI
4	Zimmermann S and Peters S: Present standards and future perspectives in the treatment of metastatic non-small cell lung cancer. Cancer Metastasis Rev. 34:173–182. 2015. View Article : Google Scholar : PubMed/NCBI
5	Azzoli CG, Giaccone G and Temin S: American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Oncol Pract. 6:39–43. 2010. View Article : Google Scholar : PubMed/NCBI
6	Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL and Paz-Ares L: Lung cancer: Current therapies and new targeted treatments. Lancet. 389:299–311. 2017. View Article : Google Scholar : PubMed/NCBI
7	Nascimento AV, Singh A, Bousbaa H, Ferreira D, Sarmento B and Amiji MM: Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles. Acta Biomater. 47:71–80. 2017. View Article : Google Scholar : PubMed/NCBI
8	Nikolaou M, Pavlopoulou A, Georgakilas AG and Kyrodimos E: The challenge of drug resistance in cancer treatment: A current overview. Clin Exp Metastasis. 35:309–318. 2018. View Article : Google Scholar : PubMed/NCBI
9	Zhang Y, Yang SH and Guo XL: New insights into Vinca alkaloids resistance mechanism and circumvention in lung cancer. Biomed Pharmacother. 96:659–666. 2017. View Article : Google Scholar : PubMed/NCBI
10	Joshi P, Vishwakarma RA and Bharate SB: Natural alkaloids as P-gp inhibitors for multidrug resistance reversal in cancer. Eur J Med Chem. 138:273–292. 2017. View Article : Google Scholar : PubMed/NCBI
11	Pesic M, Markovic JZ, Jankovic D, Kanazir S, Markovic ID, Rakic L and Ruzdijic S: Induced resistance in the human non small cell lung carcinoma (NCI-H460) cell line in vitro by anticancer drugs. J Chemother. 18:66–73. 2006. View Article : Google Scholar : PubMed/NCBI
12	Yang CH, Wang C, Ojima I and Horwitz SB: Taxol analogues exhibit differential effects on photoaffinity labeling of β-tubulin and the multidrug resistance associated P-glycoprotein. J Nat Prod. 81:600–606. 2018. View Article : Google Scholar : PubMed/NCBI
13	He J, Lan X, Duan HL, Luo H and Zhou XD: CA916798 affects growth and metastasis of androgen-dependent prostate cancer cells. Eur Rev Med Pharmacol Sci. 22:4477–4487. 2018.PubMed/NCBI
14	Wang HJ, Yang HP, Zhou XD, Dai XT, Chen YF and Xiong W: CA916798 regulates multidrug resistance of lung cancer cells. Asian Pac J Cancer Prev. 12:3403–3408. 2011.PubMed/NCBI
15	Qi Z, Wang Y and Zhou X: CA916798 gene participates in cisplatin resistance of human lung adenocarcinoma A549 cells through PI3K/AKT/mTOR pathway. Nan Fang Yi Ke Da Xue Xue Bao. 32:1290–1293. 2012.(In Chinese). PubMed/NCBI
16	Wang YL, Zhu BJ, Qi ZZ, Wang HJ and Zhou XD: Akt1 enhances CA916798 expression through mTOR pathway. PLoS One. 8:e623272013. View Article : Google Scholar : PubMed/NCBI
17	Wang HJ, Yang ZX, Dai XT, Chen YF, Yang HP and Zhou XD: Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling. Apoptosis. 22:1157–1168. 2017. View Article : Google Scholar : PubMed/NCBI
18	Yang X, Tang C, Luo H, Wang H and Zhou X: Shp2 confers cisplatin resistance in small cell lung cancer via an AKT-mediated increase in CA916798. Oncotarget. 8:23664–23674. 2017.PubMed/NCBI
19	Travis WD, Brambilla E, Rami-Porta R, Vallières E, Tsuboi M, Rusch V and Goldstraw P; International Staging Committee, : Visceral pleural invasion: Pathologic criteria and use of elastic stains: Proposal for the 7th edition of the TNM classification for lung cancer. J Thorac Oncol. 3:1384–1390. 2008. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Nishino M, Jackman DM, Hatabu H, Yeap BY, Cioffredi LA, Yap JT, Jänne PA, Johnson BE and Van den Abbeele AD: New response evaluation criteria in solid tumors (RECIST) guidelines for advanced non-small cell lung cancer: Comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol. 195:W221–W228. 2010. View Article : Google Scholar : PubMed/NCBI
22	da Costa DJ, Parrish JW, Singh NK and Hsia DW: Lung cancer: Advances and insights in diagnosis, treatment, and palliation. Am J Respir Crit Care Med. 198:667–669. 2018. View Article : Google Scholar : PubMed/NCBI
23	Zappa C and Mousa SA: Non-small cell lung cancer: Current treatment and future advances. Transl Lung Cancer Res. 5:288–300. 2016. View Article : Google Scholar : PubMed/NCBI
24	Yang P: Epidemiology of lung cancer prognosis: Quantity and quality of life. Methods Mol Biol. 471:469–486. 2009. View Article : Google Scholar : PubMed/NCBI
25	Spira A and Ettinger DS: Multidisciplinary management of lung cancer. N Engl J Med. 350:379–392. 2004. View Article : Google Scholar : PubMed/NCBI
26	Burdett SS, Stewart LA and Rydzewska L: Chemotherapy and surgery versus surgery alone in non-small cell lung cancer. Cochrane Database Syst Rev. CD0061572007.PubMed/NCBI
27	Kim ES: Chemotherapy resistance in lung cancer. Adv Exp Med Biol. 893:189–209. 2016. View Article : Google Scholar : PubMed/NCBI
28	Ullah MF: Cancer multidrug resistance (MDR): A major impediment to effective chemotherapy. Asian Pac J Cancer Prev. 9:1–6. 2008.PubMed/NCBI
29	Zahreddine H and Borden KL: Mechanisms and insights into drug resistance in cancer. Front Pharmacol. 4:282013. View Article : Google Scholar : PubMed/NCBI
30	Kartal-Yandim M, Adan-Gokbulut A and Baran Y: Molecular mechanisms of drug resistance and its reversal in cancer. Crit Rev Biotechnol. 36:716–726. 2016.PubMed/NCBI
31	Cnubben NH, Wortelboer HM, van Zanden JJ, Rietjens IM and van Bladeren PJ: Metabolism of ATP-binding cassette drug transporter inhibitors: Complicating factor for multidrug resistance. Expert Opin Drug Metab Toxicol. 1:219–232. 2005. View Article : Google Scholar : PubMed/NCBI
32	Sodani K, Patel A, Kathawala RJ and Chen ZS: Multidrug resistance associated proteins in multidrug resistance. Chin J Cancer. 31:58–72. 2012. View Article : Google Scholar : PubMed/NCBI
33	Choi CH: ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int. 5:302005. View Article : Google Scholar : PubMed/NCBI
34	Leslie EM, Deeley RG and Cole SP: Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol. 204:216–237. 2005. View Article : Google Scholar : PubMed/NCBI
35	Triller N, Korosec P, Kern I, Kosnik M and Debeljak A: Multidrug resistance in small cell lung cancer: Expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease. Lung Cancer. 54:235–240. 2006. View Article : Google Scholar : PubMed/NCBI
36	Roy S, Kenny E, Kennedy S, Larkin A, Ballot J, Perez De Villarreal M, Crown J and O'Driscoll L: MDR1/P-glycoprotein and MRP-1 mRNA and protein expression in non-small cell lung cancer. Anticancer Res. 27:1325–1330. 2007.PubMed/NCBI
37	Melguizo C, Prados J, Luque R, Ortiz R, Caba O, Alvarez PJ, Gonzalez B and Aranega A: Modulation of MDR1 and MRP3 gene expression in lung cancer cells after paclitaxel and carboplatin exposure. Int J Mol Sci. 13:16624–16635. 2012. View Article : Google Scholar : PubMed/NCBI
38	Chan BA and Coward JI: Chemotherapy advances in small-cell lung cancer. J Thorac Dis. 5 (Suppl 5):S565–S578. 2013.PubMed/NCBI